Saya Biologics partners with global biologic developers to register, market, and distribute innovative biologic and biosimilar medicines across Latin America. By using a digital supply‑chain platform and agile processes, it ensures reliable, cost‑effective access for hospitals, health systems, and patients while meeting international quality and regulatory standards.
Funding
Funding not disclosed
Founders
Product
Problem
Patients in Latin America often lack timely and affordable access to high‑quality biological and biosimilar medicines due to limited local manufacturing, fragmented distribution networks, and high entry costs for new therapies.
Solution
Saya Biologics addresses this gap by forming international partnerships to register, market, and distribute innovative biologics and biosimilars across LATAM markets. Leveraging a digital infrastructure and agile operational processes, the company ensures a reliable supply chain, regulatory compliance, and cost‑effective pricing. By focusing on precision, efficiency, and patient‑centered priorities, Saya accelerates the introduction of therapies that meet regional healthcare needs while maintaining rigorous quality and safety standards.
Target Audience
Primary customers are healthcare providers, hospitals, and national health systems in Latin America seeking affordable biologic and biosimilar therapies, as well as pharmaceutical partners looking to enter or expand within the region.
Features
- Strategic alliances with global biologic developers to secure licensing and technology transfer for LATAM markets
- End‑to‑end regulatory support for product registration, ensuring compliance with local health authorities
- Integrated digital supply‑chain platform that monitors inventory, demand forecasting, and distribution logistics
- Quality‑assured manufacturing and packaging processes that meet international biosimilar standards
- Pricing models designed to lower acquisition costs and improve reimbursement eligibility for public and private payers